Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

Presents At ASCO On Multiple Assets

 
• By Xu Hu
  
An executive interview with two microphones
Innovent builds in-house and partnered pipeline including mazdutide, originally licensed from Lilly and expected to be approved in China this year for obesity and type 2 diabetes. (Shutterstock/AI-generated)

More from China

More from Leadership